Specifically, all grades colitis, hypophysis, and rash were more common with CTLA-4 inhibitors, whereas PD-1 inhibitors had increased risk for development of pneumonitis, hypothyroidism, arthralgia, and vitiligo (85). Here, CTLA4 is linked to hypophysitis.